BerandaN1BI34 • BVMF
add
Neurocrine Biosciences Bdr
Tutup sebelumnya
R$37,77
Rentang hari
R$37,48 - R$38,32
Rentang tahun
R$25,64 - R$44,95
Kapitalisasi pasar
14,14Â M USD
Volume Rata-Rata
827,00
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 794,90Â jt | 27,78% |
Biaya operasional | 291,60Â jt | 24,46% |
Penghasilan bersih | 209,50Â jt | 61,40% |
Margin laba bersih | 26,36 | 26,37% |
Penghasilan per saham | 2,17 | 19,89% |
EBITDA | 247,00Â jt | 29,12% |
Tarif pajak efektif | 28,20% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,11Â M | -9,22% |
Total aset | 4,27Â M | 20,67% |
Total liabilitas | 1,26Â M | 54,65% |
Total ekuitas | 3,00 M | — |
Saham yang beredar | 99,71 jt | — |
Harga terhadap nilai buku | 1,25 | — |
Tingkat pengembalian aset | 14,67% | — |
Tingkat pengembalian modal | 17,95% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 209,50Â jt | 61,40% |
Kas dari operasi | 227,50Â jt | 43,99% |
Kas dari investasi | -196,70Â jt | -896,36% |
Kas dari pembiayaan | 45,60Â jt | 72,73% |
Perubahan kas bersih | 76,20Â jt | -63,61% |
Arus kas bebas | -35,14Â jt | -237,86% |
Tentang
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Didirikan
1992
Kantor pusat
Situs
Karyawan
1.800
